The current state and future directions of RNAi-based therapeutics

By Ryan L Setten, John J. Rossi, Si-ping Han. Nature reviews. Drug discovery, 2019

1,163 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/7803dd14aefb7ba46537577c5d52f692e2544a6f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. M. Manoharan
2. C. Crews
3. George M. Burslem

In Molecular Biology

1. George M. Burslem
2. M. Manoharan
3. Martin Egli
4. C. Crews

Citations in the corpus

• Proteolysis Targeting Chimeras as Therapeutics and Tools for Biological Discovery (2020, positive): “This allows for the direct comparison of degradation versus inhibition with the same methodology, resulting in an enhanced biological understanding of protein function and abrogating the risks of perturbing complex biological systems with, for example, transfection reagents that may either induce ef”
• Chemistry, structure and function of approved oligonucleotide therapeutics (2023, background): “The presence of two strands and the lack of proper discrimination between them can trigger an off-target effect (OTE) (296,297,299).”